Pharmaceuticals

Anti-Cancer MAbS Sector Forecast Shows Robust Momentum, Climbing to $112.41 Billion With 9.5% CAGR

February 12, 2026February 12, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the anti-cancer mabs market from 2026–2035 with trusted insights from The Business Research Company

What is the estimated market size of the Anti-Cancer MAbS Market by the end of 2030?

The anti-cancer mabs market size has shown robust expansion in recent years. It is anticipated to grow from $71.25 billion in 2025 to $78.12 billion in 2026, registering a compound annual growth rate (CAGR) of 9.6%. This historical growth can be linked to factors like the escalating global incidence of cancer, the clinical achievements of monoclonal antibodies, substantial investment in oncology research and development, regulatory clearances for biologics, and enhanced survival outcomes in cancer treatment.

The anti-cancer mabs market is projected to experience robust expansion in the coming years, set to reach a valuation of $112.41 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 9.5%. This anticipated growth during the projection period stems from several factors, including the development of personalized cancer medicine, the proliferation of biosimilar mAbs, increased expenditure on oncology healthcare, innovations in antibody engineering, and broader availability of biologic therapies. Key trends foreseen for this period encompass the growing acceptance of targeted immunotherapies, the wider application of humanized and bispecific antibodies, the increasing utilization of combination cancer treatments, a heightened emphasis on precision oncology, and enhanced manufacturing capabilities for mAbs.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9041&type=smp

What Drivers Are Shaping Future Opportunities In The Anti-Cancer MAbS Market?

The global rise in cancer cases is anticipated to drive the expansion of the anticancer mAbs market in the foreseeable future. Cancer is defined as a collection of illnesses marked by uncontrolled cellular proliferation, capable of invading and damaging healthy body tissues. This growing incidence of cancer can be attributed to factors such as aging demographics, evolving lifestyles, environmental factors, and improved diagnostic technologies leading to earlier and more frequent detection. Anticancer monoclonal antibodies (mAbs) function by attaching to specific proteins found on cancerous cells, utilizing genetically engineered forms of the immune system’s own antibodies to identify and eradicate these cells. Consequently, a higher prevalence of cancer boosts the demand for the anticancer mAbs market. For example, in February 2024, the World Health Organization (WHO), a United Nations agency based in Switzerland, reported a projection of new cancer cases surpassing 35 million by 2050, which signifies a 77% increase from the approximate 20 million cases recorded in 2022. As a result, the escalating global prevalence of cancer is propelling the growth of the anticancer mAbs market.

Which Segment Groups Are Influencing The Anti-Cancer MAbS Market?

The anti-cancer mabs market covered in this report is segmented –

1) By Type: Murine Antibodies, Chimeric Antibodies, Humanized Antibodies, Other Types

2) By Application: Blood Cancer, Breast Cancer, Lung Cancer, Melanoma, Colorectal Cancer, Liver Cancer, Other Applications

3) By End User: Hospitals, Research Institutes, Other End Users

Subsegments:

1) By Murine Antibodies: Murine IgG, Murine IgM, Other Murine Isotypes

2) By Chimeric Antibodies: Chimeric IgG, Chimeric IgM, Other Chimeric Isotypes

3) By Humanized Antibodies: Humanized IgG, Humanized IgM, Other Humanized Isotypes

4) By Other Types: Fully Human Antibodies, Bispecific Antibodies, Conjugated Antibodies, Other Novel Formats

Which Trends Are Shaping Activity Within The Anti-Cancer MAbS Market?

Major companies operating within the anti-cancer monoclonal antibodies (mAbs) market are prioritizing the development of innovative solutions, such as early-phase clinical trials, to advance novel therapeutic candidates and strengthen their competitive stance. Clinical trials are structured research studies carried out in human participants to evaluate the safety, appropriate dosing, and therapeutic effectiveness of new medical interventions, including targeted antibodies and radioimmunotherapies. For instance, in April 2023, Y-mAbs Therapeutics Inc., a US-based clinical biopharmaceutical company, initiated a Phase I clinical trial to evaluate GD2-SADA. This pre-targeted radioimmunotherapy is designed for GD2-positive solid tumors like small cell lung cancer, sarcoma, and malignant melanoma. The therapy employs a two-step mechanism where the SADA protein first selectively binds to GD2-expressing tumor cells, followed by the administration of the radioactive ligand 177Lu-DOTA, which then attaches to the SADA protein to deliver targeted radiation, with the goal of maximizing tumor cell destruction while minimizing radiation exposure to healthy tissues.

Who Are The Major Companies Operating In The Anti-Cancer MAbS Market?

Major companies operating in the anti-cancer mabs market are Amgen Inc., Bristol Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Johnson & Johnson, Novartis AG, Merck & Co. Inc., Spectrum Pharmaceuticals Inc., AstraZeneca plc., Pfizer Inc., Gilead Sciences Inc., Bayer HealthCare, ImmunoGen Inc., Genentech Inc., AbbVie Inc., Takeda Pharmaceuticals, Seattle Genetics, Regeneron Pharmaceuticals, Celgene, Ipsen, Daiichi Sankyo, ADC Therapeutics, MacroGenics Inc., Zymeworks Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/anti-cancer-mabs-global-market-report

Which Region Is Anticipated To See The Fastest Growth In The Anti-Cancer MAbS Market?

North America was the largest region in the anti-cancer MAbS market in 2025. Asia-Pacific is expected to be the fastest-growing region in the anti-cancer MAbS market during the forecast period. The regions covered in the anti-cancer mabs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Anti-Cancer MAbS Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=9041&type=smp

Browse Through More Reports Similar to the Global Anti-Cancer MAbS Market 2026, By The Business Research Company

Anti Cancer Mabs Market Report 2026

https://www.thebusinessresearchcompany.com/report/anti-cancer-mabs-global-market-report

Monoclonal Antibodies Market Report 2026

https://www.thebusinessresearchcompany.com/report/monoclonal-antibodies-global-market-report

Monoclonal Antibodies Market Report 2026

https://www.thebusinessresearchcompany.com/report/monoclonal-antibodies-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795